Examining differences in fat-derived extracellular vesicles in obese individuals.
Official title: The Adipose Tissue and Sex-specific Role of Adipose-derived Extracellular Vesicles in Obesity-related Skeletal Muscle Insulin Resistance.
Run by Hasselt University · NCT06444646 · Data updated 2026-11-12
This study looks at how tiny particles from fat cells in people with obesity differ from those in lean individuals to see how these differences might affect health issues like insulin sensitivity and heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Hasselt University Academic / other |
| Locations | 1 site (Genk, Limburg) |
| Status | Recruiting |
| Started | February 20, 2023 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | September 15, 2025 |
| Trial ID | NCT06444646 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include Caucasian adults with obesity (BMI ≥ 35 kg/m²) scheduled for bariatric surgery, as well as lean Caucasian females (BMI 18-24.9 kg/m²) scheduled for abdominal surgery.
✕Probably not a fit
Patients with cardiovascular, lung, kidney, brain, or malignant diseases, as well as those who smoke or abuse drugs, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the differences in extracellular vesicles (EVs) derived from adipose tissue in individuals with obesity compared to lean individuals. It focuses on how these differences may relate to factors such as sex, insulin sensitivity, and the function of the blood-brain barrier. The study involves adipose tissue biopsies, blood sampling, and patient phenotyping to analyze the EV profiles from fat and immune cells. By understanding these differences, the research aims to shed light on the mechanisms linking obesity to related metabolic and cardiovascular diseases.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of obesity's role in metabolic diseases and lead to improved treatment strategies.
How similar studies have gone: While the specific focus on EVs from adipose tissue in this context may be novel, similar studies have shown promising results in understanding obesity-related mechanisms.
Who can join: the full rules
Show full inclusion / exclusion criteria
Individuals with obesity - Inclusion Criteria: * Caucasian adults with obesity that have a body mass index (BMI) of at least 35 kg/m\^2 and are scheduled for their first bariatric surgery. * Final male/female ratio of this study is 1:1 * Minimal knowledge of Dutch to read and understand the informed consent. Individuals with obesity - Exclusion Criteria: * Smoking and/or drug abuse * Cardiovascular diseases (including but not limited to implanted aids like a pacemaker or defibrillator) * Lung and/or kidney diseases * Brain and/or nerve diseases * Malignant diseases (e.g. cancer) Individuals without obesity (lean) - inclusion criteria * Caucasian adults with obesity that have a body mass index (BMI) of between 18 and 24.9 kg/m\^2 and are scheduled for abdominal surgery * Female only * Minimal knowledge of Dutch to read and understand the informed consent. Individuals without obesity (lean) - exclusion criteria * Smoking and/or drug abuse * Cardiovascular diseases (including but not limited to implanted aids like a pacemaker or defibrillator) * Lung and/or kidney diseases * Brain and/or nerve diseases * Endocrine diseases like type 2 diabetes * Malignant diseases (e.g. cancer)
Where it's running
-
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium Recruiting
Study contacts
- Study coordinator: Lisa Mennens
- Email: lisa.mennens@uhasselt.be
- Phone: +32 (0)499 / 72 29 93
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.